Patent · US Active

Engineered CRISPR-Cas9 nucleases

US10526591B2 · kind B2 · utility

13Cited by

26References

32Claims

0Family size

Assignee

The General Hospital Corporation · US

Inventors

J. Keith Joung · Winchester, US
Benjamin Kleinstiver · Medford, US
Vikram Pattanayak · Wellesley, US

Key dates

Filing date	Mar 26, 2018
Grant date	Jan 7, 2020
Priority date	—
Expiry date	May 19, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/22
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Engineered CRISPR-Cas9 nucleases with improved specificity and their use in genomic engineering, epigenomic engineering, genome targeting, and genome editing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.